Alkermes

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Alkermes and other ETFs, options, and stocks.

About ALKS

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL.

CEO

Blair C. Jackson

CEOBlair C. Jackson

Employees

2,050

Employees2,050

Headquarters

Dublin, Dublin

HeadquartersDublin, Dublin

Founded

2011

Founded2011

Employees

2,050

Employees2,050

ALKS Key Statistics

Market cap

8.01B

Market cap8.01B

Price-Earnings ratio

-3,495.62

Price-Earnings ratio-3,495.62

Dividend yield

—

Dividend yield—

Average volume

1.66M

Average volume1.66M

High today

$48.35

High today$48.35

Low today

$44.58

Low today$44.58

Open price

$45.93

Open price$45.93

Volume

1.99M

Volume1.99M

52 Week high

$55.67

52 Week high$55.67

52 Week low

$27.00

52 Week low$27.00

Stock Snapshot

With a market cap of 8.01B, Alkermes(ALKS) trades at $47.66. The stock has a price-to-earnings ratio of -3495.62.

On 2026-11-12, Alkermes(ALKS) stock moved within a range of $44.58 to $48.35. With shares now at $47.66, the stock is trading +6.9% above its intraday low and -1.4% below the session's peak.

Trading volume for Alkermes(ALKS) stock has reached 1.99M, versus its average volume of 1.66M.

The stock's 52-week range extends from a low of $27.00 to a high of $55.67.

ALKS News

TipRanks 3h

Alkermes position intact after Takeda drug pricing, says Needham

Needham keeps a Buy rating on Alkermes (ALKS) after Takeda (TAK) announced the U.S. launch of Orzeyful with a flat list price of $16,500 per 60 tablets, across...

TipRanks 5h

Alkermes and Teva Resolve LYBALVI Patent Litigation - TipRanks

...

Simply Wall St 6h

Clinical Data Wave Might Change The Case For Investing In Alkermes Stock

Alkermes reported third quarter 2026 revenue of US$480.13 million and net income of US$16.29 million, alongside extensive psychiatry and sleep medicine data pre...

Analyst ratings

76%

of 17 ratings

Buy

76.5%

Hold

17.6%

Sell

5.9%

More ALKS News

Simply Wall St 4d

Why Did Alkermes Shares Climb After Its Latest Update?

Alkermes (ALKS) has been in focus after announcing extensive new data presentations across its psychiatry and sleep medicine franchises, along with the launch o...

People also own

Based on the portfolios of people who own ALKS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.